

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63

August 23, 2021

ISSUE No.
1631

IN THIS ISSUE

In Brief: *Shingrix* for Immunocompromised Adultsp 129

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63 (Issue 1631)

August 23, 2021

Take CME Exams

IN BRIEF

Shingrix for Immunocompromised Adults

The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine *Shingrix* (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression. *Shingrix* has been licensed for herpes zoster prevention in adults ≥ 50 years old since 2017.¹ It is the only VZV vaccine currently available in the US; *Zostavax*, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.

FDA licensure of *Shingrix* for the new indication was based on the results of two studies: a randomized, placebo-controlled trial in 1846 immunocompromised adults ≥ 18 years old who had received an autologous hematopoietic stem cell transplant within the previous 50-70 days, and a post-hoc analysis of a similar trial in 569 adults who were receiving immunosuppressive

therapy for hematologic malignancies. In both trials, *Shingrix* significantly decreased the incidence of herpes zoster occurring ≥ 1 month after the second dose compared to placebo (see Table 1).^{2,3}

Adverse effects of *Shingrix* in immunocompromised persons appear to be similar to those in healthy older adults. Myalgia, fatigue, headache, shivering, fever, GI symptoms, and injection-site pain, redness, and swelling are common. Severe local reactions preventing normal daily activities can occur.^{1,4} In a postmarketing observational study in adults ≥ 65 years old, use of *Shingrix* was associated with an increased risk of Guillain-Barré syndrome in the 6 weeks after vaccination.⁵

In healthy older adults, *Shingrix* is typically given as two 0.5-mL doses administered intramuscularly 2-6 months apart. For immunocompromised patients who would benefit from a shorter vaccination schedule, the second dose can be given as early as 1 month after the first. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) on use of the vaccine in immunocompromised persons were not available at press time. ■

Table 1. Some *Shingrix* Clinical Trial Results

Treatment ¹	Herpes Zoster Incidence Rate ²	Vaccine Efficacy
Trial 1 (auHSCT; n=1846) ³		
<i>Shingrix</i>	30.0	68.2%
Placebo	94.3	
Trial 2 (hematologic malignancies; n=569) ⁴		
<i>Shingrix</i>	8.5	87.2%
Placebo	66.2	

auHSCT = autologous hematopoietic stem cell transplant

- Given as 2 doses IM 1-2 months apart.
- Herpes zoster incidence per 1000 patient-years from 1 month after the second dose. Measured among patients who received both doses and did not develop herpes zoster before or < 1 month after the second dose. The primary endpoint in trial 1 and a post-hoc endpoint in trial 2.
- In immunocompromised adults who had undergone auHSCT 50-70 days before randomization. Median follow-up was 21 months. A Bastidas et al. JAMA 2019; 322:123.
- In adults who were receiving immunosuppressive therapy for hematologic malignancies. Median follow-up was 13 months. AF Dagnev et al. Lancet Infect Dis 2019; 19:988.

- Shingrix* – an adjuvanted, recombinant herpes zoster vaccine. Med Lett Drugs Ther 2017; 59:195.
- A Bastidas et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 2019; 322:123.
- AF Dagnev et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19:988.
- M López-Fauqued et al. Safety profile of the adjuvanted recombinant zoster vaccine in immunocompromised populations: an overview of six trials. Drug Saf 2021; 44:811.
- FDA Safety Communication. FDA requires a warning about Guillain-Barré Syndrome (GBS) be included in the prescribing information for *Shingrix*. March 24, 2021. Available at: <https://bit.ly/3lmyvC6>. Accessed August 3, 2021.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
 www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
 please e-mail your request to:
 permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:  

Copyright 2021. ISSN 1523-2859

The
 Medical
 Letter